Breast cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Goserelin monotherapy Variant #04 | ER | R 10 511 | 84d | — | — | — | — | — |
Tamoxifen and OFS Variant not yet assigned - class-based regimen | ER | R 6 366 | 28d | — | — | — | — | 3 |
Goserelin and Tamoxifen Variant #01 | ER | R 2 764 | 28d | ~13.0 mo | ~48.0 mo | ~15 | ~R 41 467 PFS proxy · indirect | 2 |
Leuprolide monotherapy Variant #01 | ER | R 2 266 | 90d | — | — | — | — | 2 |
Exemestane and OFS Variant #01 | ER | R 1 859 | 28d | — | — | — | — | — |
Tamoxifen monotherapy Variant #06 | ER | R 410 | 28d | — | — | — | — | 3 |
6 of 6 regimens shown